FDA's traditional approval for Imdelltra followed 2024 accelerated nodNov 12Regulatory decisionAmgentarlatamab-dlleUpdated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
AbbVie posts KEEPsAKE 2 update; registers pediatric vitiligo and real-world MIRV studiesOct 29Weekly roundup, 7 itemsABBV-706ABBV-722Updated
Amgen updates IMDELLTRA label via BLA supplement; registers romosozumab bioavailability trialSep 11Weekly roundup, 2 itemsAmgenromosozumab-aqqg
Amgen registers Phase 3 trial comparing subcutaneous and IV tarlatamab in relapsed ES-SCLCAug 21Trial updateAmgentarlatamab-dlle
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestonesAug 6Quarterly updateZai Lab (Shanghai) Co., Ltd.ZL-1503
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2Aug 5Quarterly updateRoyalty Pharma plc